Rgn

Life Edit Therapeutics to Present Data Demonstrating Therapeutic Potential of its Novel Gene Editing Platform

Retrieved on: 
Tuesday, April 25, 2023

Life Edit’s presentations underscore the ability of its gene editing platform to selectively target disease-associated genetic factors to treat life-threatening diseases.

Key Points: 
  • Life Edit’s presentations underscore the ability of its gene editing platform to selectively target disease-associated genetic factors to treat life-threatening diseases.
  • Wild-type HTT protein is purported to be physiologically critical, hence selective editing of the mutant HTT (mutHTT) protein is necessary for therapeutic benefit.
  • AAV5-delivered Life Edit gene editing systems enabling allele-specific targeting of mutant HTT demonstrated dose-response reductions in striatal mutHTT protein with clinically meaningful reductions of >50% observed.
  • Our recent technology advancements will help us to further power the Life Edit gene editing platform, support our partners, and selectively build out our pipeline of innovative therapeutic candidates."

Life Edit Therapeutics Appoints Joy A. Cavagnaro to Its Scientific Advisory Board

Retrieved on: 
Wednesday, June 29, 2022

Life Edit Therapeutics Inc., an ElevateBio company focused on next-generation genome editing technologies and therapeutics, today announced the appointment of Joy A. Cavagnaro, Ph.D., DABT, Fellow ATS, RAC, FRAPS, to its Scientific Advisory Board (SAB).

Key Points: 
  • Life Edit Therapeutics Inc., an ElevateBio company focused on next-generation genome editing technologies and therapeutics, today announced the appointment of Joy A. Cavagnaro, Ph.D., DABT, Fellow ATS, RAC, FRAPS, to its Scientific Advisory Board (SAB).
  • We are thrilled to welcome Joy to our Scientific Advisory Board as we rapidly advance our gene editing platform to harness the vast potential of our novel nucleases and base editors as therapeutics, said Mitchell Finer, Ph.D., Chief Executive Officer, Life Edit Therapeutics and President, R&D, ElevateBio.
  • Joys expertise in drug discovery and development will complement our esteemed Scientific Advisory Board slate, and collectively our advisors will continue to help Life Edit and our partners further therapeutic programs to address the tremendous unmet needs of genetically-defined diseases.
  • About Life Edit Therapeutics Inc.
    Life Edit Therapeutics, an ElevateBio company, is a next-generation genome editing company that has built a highly innovative platform with one of the worlds largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors.

The Third Annual Public Health Genetics Week is Around the Corner - May 23-27, 2022

Retrieved on: 
Tuesday, May 10, 2022

BETHESDA, Md., May 10, 2022 (GLOBE NEWSWIRE) -- The National Coordinating Center for the Regional Genetics Network ( NCC ) is excited to announce that the third annual Public Health Genetics Week will be held from May 23-27, 2022.

Key Points: 
  • BETHESDA, Md., May 10, 2022 (GLOBE NEWSWIRE) -- The National Coordinating Center for the Regional Genetics Network ( NCC ) is excited to announce that the third annual Public Health Genetics Week will be held from May 23-27, 2022.
  • The goal of Public Health Genetics Week is to increase awareness and celebrate the field of public health genetics.
  • Each day of Public Health Genetics Week will have a different theme:
    Individuals and organizations are encouraged to participate in the week by using the hashtags #PHGW and #PublicHealthGenetics across their social media platforms.
  • A number of events will be held throughout the week to celebrate public health genetics for professionals, students, and the general public.

ElevateBio Announces Issuance of U.S. Patent Providing Protection for RNA-Guided Nucleases Identified through its Life Edit Gene Editing Platform

Retrieved on: 
Monday, November 15, 2021

This patent, issued to LifeEDIT Therapeutics, Inc. (Life Edit), is the first to provide composition and methods of use protection for various RNA-guided nucleases (RGNs) in Life Edits gene editing platform.

Key Points: 
  • This patent, issued to LifeEDIT Therapeutics, Inc. (Life Edit), is the first to provide composition and methods of use protection for various RNA-guided nucleases (RGNs) in Life Edits gene editing platform.
  • Life Edit is an ElevateBio company and holds an array of novel RGNs and base editors.
  • "This patent issuance marks an important milestone for the Life Edit gene editing platform and is an acknowledgement of the uniqueness of our powerful suite of editing systems," said Mitchell Finer, Ph.D., President, R&D of ElevateBio and Chief Executive Officer of Life Edit.
  • ElevateBio is a cell and gene therapy technology company designed to power the development and manufacturing of transformative cell and gene therapies.

ElevateBio Supercharges Gene Editing and Therapeutic Product Development Capabilities Through Acquisition of Life Edit Therapeutics

Retrieved on: 
Wednesday, October 27, 2021

ElevateBio, LLC (ElevateBio), a cell and gene therapy technology company focused on powering transformative cell and gene therapies, today announced that it has acquired all of AgBiome Delta, LLCs (AgBiome) shares of Life Edit Therapeutics, Inc. (Life Edit).

Key Points: 
  • ElevateBio, LLC (ElevateBio), a cell and gene therapy technology company focused on powering transformative cell and gene therapies, today announced that it has acquired all of AgBiome Delta, LLCs (AgBiome) shares of Life Edit Therapeutics, Inc. (Life Edit).
  • Life Edit offers a powerful suite of gene editing technologies that have the potential for any genomic sequence of interest to be removed, added, or altered.
  • Life Edit was spun out of AgBiome in October 2020 and AgBiome continues to retain rights for gene editing outside of human therapeutics.
  • Life Edit has identified several classes of DNA modifying enzymes, including novel deaminases that can edit cytidine (C) or adenine (A).

ARISE-3 Phase 3 Trial Completion Expected by End of 2020

Retrieved on: 
Wednesday, October 14, 2020

"We are pleased ARISE-3 is near completion, despite the challenges posed by the COVID-19 pandemic.

Key Points: 
  • "We are pleased ARISE-3 is near completion, despite the challenges posed by the COVID-19 pandemic.
  • This phase 3 trial is a critical milestone in the development of RGN-259 for dry eye syndrome and crucial to our future success.
  • We look forward to announcing top line results as soon as practicable upon completion of the trial," stated J.J. Finkelstein, president and chief executive.
  • RGN-259, the Company's ophthalmic eye drop, is currently in phase 3 development in the U.S. for dry eye syndrome and neurotrophic keratitis.